<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169818</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_R_04889</org_study_id>
    <secondary_id>U1111-1116-2247</secondary_id>
    <nct_id>NCT01169818</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>Asian Treat to Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating the Effectiveness and Safety of Physician Versus Patient-led Initiation and Titration of Insulin Glargine in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To compare patient-led titration (intervention group) versus physician-led titration (usual&#xD;
      standard of care) in optimizing the clinical use of insulin glargine in an Asian population&#xD;
      of patients with Type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetic drugs&#xD;
      (OADs).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To determine the difference in glycemic control, safety, quality of life and treatment&#xD;
      satisfaction between patient-led titration and usual care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change (decrease) in mean hemoglobin glycosylated (HbA1c) level</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving HbA1c levels &lt; 7.0% without experiencing severe hypoglycemia</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving target HbA1c levels (&lt; 7.0% and &lt;6.5%)</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients having a drop of 1% in HbA1c levels and/or a drop of at least 0.5%.</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Fasting Plasma glucose (FPG) and Post Prandial blood Glucose (PPG)</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Blood Glucose profiles</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic hypoglycemia</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of nocturnal hypoglycemia</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of asymptomatic hypoglycemia</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in body weight in patients</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean insulin dose</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMs (patient reported outcome measures) scores from the DTSQs/c (diabetes treatment satisfaction questionnaire status) and EQ-5D (European quality of life - 5 dimensions)</measure>
    <time_frame>from week 0 (baseline) to week 24 (end of study)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">555</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual standard of care group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous&#xD;
Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Usual standard of care group</arm_group_label>
    <other_name>Solostar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Diagnosed with T2DM duration of T2DM &gt; 2 years&#xD;
&#xD;
          2. Insulin na√Øve&#xD;
&#xD;
          3. Continuous treatment with stable doses of 2 OADs (sulphonylureas, biguanides,&#xD;
             alpha-glucosidase inhibitors, DPP-IV inhibitors, and glinides) for &gt; three months&#xD;
             prior to randomization&#xD;
&#xD;
          4. HbA1c levels 7% and 11 %&#xD;
&#xD;
          5. Body mass index (BMI) 20 and 40 kg/m2&#xD;
&#xD;
          6. Willing and able to perform blood glucose monitoring using a blood glucose meter&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Diabetes other than type 2 diabetes (e.g. secondary to pancreatic disorders, drug or&#xD;
             chemical agent intake),&#xD;
&#xD;
          2. Current or previous use of insulin (except for previous treatment of gestational&#xD;
             diabetes or brief treatment with insulin for &lt; 1 week),&#xD;
&#xD;
          3. Current treatment with thiazolidinediones,&#xD;
&#xD;
          4. Current or previous use (within the last 3 months) of GLP-1 receptor agonists or GLP-1&#xD;
             analogues,&#xD;
&#xD;
          5. Current or previous (within the last 3 months) use of any treatment for weight lost,&#xD;
&#xD;
          6. Active proliferative diabetic retinopathy,&#xD;
&#xD;
          7. Patient without any history of eye examination in the past 6 months,&#xD;
&#xD;
          8. Treatment with systemic corticosteroids in the 3 months prior to study entry,&#xD;
&#xD;
          9. Currently receiving treatment with monoamine oxidase inhibitors,&#xD;
&#xD;
         10. Currently receiving treatment with non-selective -blockers,&#xD;
&#xD;
         11. Treatment with any investigational product and/or device in the 2 months prior to&#xD;
             study entry,&#xD;
&#xD;
         12. Likelihood of requiring treatment during the study period with drugs not permitted by&#xD;
             the clinical trial protocol,&#xD;
&#xD;
         13. History of ketoacidosis or hyperosmolar hyperglycemic state,&#xD;
&#xD;
         14. History of stroke, myocardial infarction, angina pectoris, coronary artery bypass&#xD;
             graft or percutaneous transluminal coronary angioplasty within the previous 12 months,&#xD;
&#xD;
         15. History of congestive heart failure,&#xD;
&#xD;
         16. History of hypoglycemia unawareness,&#xD;
&#xD;
         17. Unexplained hypoglycemia in the past 6 months,&#xD;
&#xD;
         18. Impaired renal function defined as, but not limited to, serum creatinine 1.5 mg/dL&#xD;
             (133 mol/L) males or 1.4 mg/dL (124 mol/L) females or presence of macroproteinuria&#xD;
             (&gt;2gr/day),&#xD;
&#xD;
         19. Active liver disease (alanine transaminase ALAT greater than two times the upper limit&#xD;
             of the reference range, as defined by the local laboratory),&#xD;
&#xD;
         20. Have any condition (including known substance or alcohol abuse or psychiatric&#xD;
             disorder) that precludes the patient from following and completing the study protocol,&#xD;
&#xD;
         21. Had a blood transfusion or severe blood loss within the 3 months before screening, or&#xD;
             have known hemoglobinopathy, hemolytic anemia or sickle cell anemia,&#xD;
&#xD;
         22. Known hypersensitivity / intolerance to insulin glargine or any of its excipients,&#xD;
&#xD;
         23. History of pancreatitis,&#xD;
&#xD;
         24. Currently undergoing therapy or planned radiological examinations requiring the&#xD;
             administration of contrasting agents for malignancy (other than non-metastatic / early&#xD;
             stage basal cell or squamous cell carcinoma),&#xD;
&#xD;
         25. Pregnant or lactating women (women of childbearing potential must have a negative&#xD;
             pregnancy test at study entry and a medically approved contraception method),&#xD;
&#xD;
         26. Any medical condition that may have an influence on HbA1c rate.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Japan</country>
    <country>Pakistan</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>ATLAS Study Group. Titration of Insulin Glargine in Patients with Type 2 Diabetes Mellitus in Asia: Physician- Versus Patient-Led? Rationale of the Asian Treat to Target Lantus Study (ATLAS). Diabetes Technol Ther. 2011 Jan;13(1):67-72. doi: 10.1089/dia.2010.0170.</citation>
    <PMID>21175274</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <last_update_submitted>July 5, 2013</last_update_submitted>
  <last_update_submitted_qc>July 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

